Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 51 Publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):52

PubMed: 28403890 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(3)

PubMed: 27993855 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2015, 15:97

PubMed: 26464561 ( click the link to review the publication )

Int J Oncol, 2015, 46(4):1844-8

PubMed: 25647738 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Mol Cells, 2015, 38(3):279-84

PubMed: 25666350 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )
Endocr Relat Cancer, 2014, 21(5):755-67

PubMed: 25012986 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2789-94

PubMed: 25333301 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(4):448-59

PubMed: 23395885 ( click the link to review the publication )

J Immunol, 2013, 190(9):4621-6

PubMed: 23547112 ( click the link to review the publication )

Apoptosis, 2013, 18(10):1163-74

PubMed: 23887890 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(4):609-18

PubMed: 23668615 ( click the link to review the publication )

Exp Cell Res, 2013, 319(10):1443-50

PubMed: 23416067 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

BMC Cancer, 2011, 11:24

PubMed: 21247487 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXV[WJKSzVyPUCuNFAxODNzNzFOwG0>	M{S1e3NCVkeHUh?=
SK-MEL-30	NG\CdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrRVoNKSzVyPUCuNFAxOzV3IN88US=>	NXT3fWpiW0GQR1XS
NALM-6	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVK1OIl{UUN3ME2wMlAxODN3NjFOwG0>	NWfGWXk6W0GQR1XS
KYSE-450	NFfRZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLZTWM2OD1yLkCwNFQ3QSEQvF2=	MkWyV2FPT0WU
BHY	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfwTWM2OD1yLkCwNFYxOSEQvF2=	NEKxN5FUSU6JRWK=
GR-ST	NFnT[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjHXWRKSzVyPUCuNFAxPjR6IN88US=>	MmH0V2FPT0WU
786-0	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDYTWM2OD1yLkCwNFc4PiEQvF2=	MkSzV2FPT0WU
C-33-A	NF;lXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMECwPFQ5KM7:TR?=	MnzFV2FPT0WU
BHT-101	M3rqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKyV2pKSzVyPUCuNFAyODZizszN	MYXTRW5ITVJ?
EB2	NXzr[FM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfmSFE6UUN3ME2wMlAxOTF6IN88US=>	NVLuNFVOW0GQR1XS
G-361	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXNTWM2OD1yLkCwNVI1KM7:TR?=	M3TmZ3NCVkeHUh?=
KE-37	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fHV2lEPTB;MD6wNFEzQCEQvF2=	NW[2eGlEW0GQR1XS
MHH-PREB-1	NYTIRXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\jTWM2OD1yLkCwNVQh\|ryP	NEHsTI1USU6JRWK=
MCF7	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFOxb2lKSzVyPUCuNFAyPTlizszN	NEjxWpBUSU6JRWK=
LOUCY	NWrxXmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\tOmlEPTB;MD6wNFE4PSEQvF2=	MYTTRW5ITVJ?
EW-7	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;yTWM2OD1yLkCwNVc2KM7:TR?=	MYfTRW5ITVJ?
KYSE-510	M1XudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXqTWM2OD1yLkCwNlM{KM7:TR?=	NILJZ5lUSU6JRWK=
SK-MEL-3	M4PDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzRbmVKSzVyPUCuNFAzPjRizszN	NILO[JlUSU6JRWK=
HAL-01	M{nVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHSPW1KSzVyPUCuNFAzQTdizszN	NFu5bphUSU6JRWK=
HCC2998	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMECzN\|Uh\|ryP	NH3ZU3NUSU6JRWK=
A375	NGjQTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfo[VVKSzVyPUCuNFA{PSEQvF2=	Mn3CV2FPT0WU
MZ7-mel	NVnUcGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULLUGxbUUN3ME2wMlAxOzl7IN88US=>	Ml3LV2FPT0WU
SH-4	NHvxcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mle4TWM2OD1yLkCwOFE4KM7:TR?=	MUjTRW5ITVJ?
HT-144	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwMEC0N{DPxE1?	MkHZV2FPT0WU
KYSE-140	M4nlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTvTWM2OD1yLkCwOFM2KM7:TR?=	M4jKW3NCVkeHUh?=
PSN1	NFnve3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVS4WI9[UUN3ME2wMlAxPDZ5IN88US=>	MVnTRW5ITVJ?
COLO-679	NGi4blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT0TWM2OD1yLkCwOFk5KM7:TR?=	MWHTRW5ITVJ?
SW620	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;5TWM2OD1yLkCwOVEyKM7:TR?=	MkTKV2FPT0WU
HGC-27	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEC1NlQh\|ryP	NUjQW3BSW0GQR1XS
IGROV-1	M3nyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2H0R2lEPTB;MD6wNFYh\|ryP	MX;TRW5ITVJ?
IGR-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnnSY1KSzVyPUCuNFA3ODFizszN	M1nyVHNCVkeHUh?=
EW-1	NFLxfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MniyTWM2OD1yLkCwOlUyKM7:TR?=	M1XPd3NCVkeHUh?=
769-P	NVLuR3pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEC2O\|gh\|ryP	M{HsUHNCVkeHUh?=
HN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;kTWM2OD1yLkCwOlc6KM7:TR?=	M1fQUXNCVkeHUh?=
SIG-M5	NI\VVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DQXGlEPTB;MD6wNFcyKM7:TR?=	MnrQV2FPT0WU
IST-MEL1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Gy[GlEPTB;MD6wNFgyQCEQvF2=	M17RVHNCVkeHUh?=
ST486	M4i1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrlTWM2OD1yLkCwPFI2KM7:TR?=	MWjTRW5ITVJ?
ES7	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHGcIxKSzVyPUCuNFA5PDZizszN	MlvtV2FPT0WU
GAK	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2W5emlEPTB;MD6wNFg1QCEQvF2=	NHfNUpFUSU6JRWK=
BB30-HNC	NWS2[IFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPtdGJKSzVyPUCuNFA5PThizszN	NV7YV29yW0GQR1XS
IPC-298	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33EO2lEPTB;MD6wNFkzPyEQvF2=	MX7TRW5ITVJ?
NKM-1	M2Ls[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7vN4FKSzVyPUCuNFA6PzJizszN	NIe3cJRUSU6JRWK=
RKO	NIXIdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HHS2lEPTB;MD6wNVA1PCEQvF2=	MXXTRW5ITVJ?
ACN	M4noeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWH3fFVLUUN3ME2wMlAyOTNzIN88US=>	NIrEPZBUSU6JRWK=
SW1417	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrwc25KSzVyPUCuNFEzOjVizszN	NUnWXoNsW0GQR1XS
SR	NFzWd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLGOm1KSzVyPUCuNFEzOzVizszN	NFzsT5pUSU6JRWK=
SNG-M	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHIT5BKSzVyPUCuNFE{OTdizszN	MVjTRW5ITVJ?
CAL-12T	NYn3Z\|hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W0WWlEPTB;MD6wNVM1PiEQvF2=	M1Tj[XNCVkeHUh?=
HSC-3	NUjqcopoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPL[npQUUN3ME2wMlAyOzV3IN88US=>	NVWyTo9lW0GQR1XS
DOHH-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Wx[2lEPTB;MD6wNVQyOiEQvF2=	Ml25V2FPT0WU
NB69	NXXTTJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLsPVU1UUN3ME2wMlAyPTZ3IN88US=>	MlvEV2FPT0WU
LC-2-ad	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTQTWM2OD1yLkCxOVgyKM7:TR?=	NX6yVHprW0GQR1XS
RVH-421	NVS5PFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHMXpg6UUN3ME2wMlAyPjd2IN88US=>	M3voSHNCVkeHUh?=
TGW	NGj6XIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M123U2lEPTB;MD6wNVc{QSEQvF2=	MlzkV2FPT0WU
HCC1569	M1rnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4GyemlEPTB;MD6wNVc6PyEQvF2=	NIL2U\|RUSU6JRWK=
CAL-85-1	MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml6zTWM2OD1yLkCxPFMzKM7:TR?=	NIHaendUSU6JRWK=
RPMI-8402	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH4TWM2OD1yLkCxPFU5KM7:TR?=	M4nmWXNCVkeHUh?=
THP-1	NGPRe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rlfGlEPTB;MD6wNVk6QCEQvF2=	MVvTRW5ITVJ?
ONS-76	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XJSmlEPTB;MD6wNlA{PiEQvF2=	MmTOV2FPT0WU
A2780	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH5VVdKSzVyPUCuNFIxPzlizszN	NWfKNIZlW0GQR1XS
RPMI-2650	M2XoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPoTWM2OD1yLkCyNlk3KM7:TR?=	NUiyR4I3W0GQR1XS
MEL-HO	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnqXJZKSzVyPUCuNFI{PDhizszN	NInHd3VUSU6JRWK=
MC-CAR	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXQTWZPUUN3ME2wMlAzOzV4IN88US=>	MVvTRW5ITVJ?
HSC-2	M4\SeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;nUJRNUUN3ME2wMlAzPDZ4IN88US=>	M3rMT3NCVkeHUh?=
MEL-JUSO	MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPBN5R[UUN3ME2wMlAzPDd\|IN88US=>	MoO3V2FPT0WU
CAL-62	NWjSe\|NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jndWlEPTB;MD6wNlYxOiEQvF2=	NYm5O\|VGW0GQR1XS
DMS-273	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEK4OFch\|ryP	NHfFWpRUSU6JRWK=
S-117	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDOTWM2OD1yLkCyPVA3KM7:TR?=	NY\XbJNyW0GQR1XS
SUP-T1	MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m3W2lEPTB;MD6wNlk1QSEQvF2=	NWflXG46W0GQR1XS
MZ2-MEL	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPTTWM2OD1yLkCyPVU6KM7:TR?=	MXrTRW5ITVJ?
KYSE-270	NYWySWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrVTWM2OD1yLkCyPVc3KM7:TR?=	M17IbHNCVkeHUh?=
CMK	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEOwNlMh\|ryP	NVG2OFUxW0GQR1XS
8505C	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjvcGZKSzVyPUCuNFMxPCEQvF2=	M1z0S3NCVkeHUh?=
NUGC-3	MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfJZ\|ZKSzVyPUCuNFMxPDhizszN	MUjTRW5ITVJ?
A101D	NHnLR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PGZmlEPTB;MD6wN\|A2PSEQvF2=	M2n5RnNCVkeHUh?=
G-401	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEOwPVMh\|ryP	M2nNN3NCVkeHUh?=
OVCAR-8	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Sxc2lEPTB;MD6wN\|ExPyEQvF2=	NIi1SXBUSU6JRWK=
IMR-5	MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTySVJKSzVyPUCuNFMzPDRizszN	Mn;qV2FPT0WU
DoTc2-4510	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PtOWlEPTB;MD6wN\|M6OyEQvF2=	NUGyU3dsW0GQR1XS
HOS	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrC[I9KSzVyPUCuNFM1PzNizszN	M1[yfHNCVkeHUh?=
HEC-1	NVnNZ\|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPITWM2OD1yLkCzOlgh\|ryP	M1KzbXNCVkeHUh?=
SW756	Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7Bd\|RKSzVyPUCuNFM5OjFizszN	NVHVUphKW0GQR1XS
NCI-H64	NYLCUZp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rwSmlEPTB;MD6wN\|g1OiEQvF2=	MXXTRW5ITVJ?
EW-16	NFXEVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr4bIRKSzVyPUCuNFM6ODlizszN	NEj0cY9USU6JRWK=
CAL-51	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDYTWM2OD1yLkC0NFA2KM7:TR?=	NFHNfW5USU6JRWK=
KYSE-150	NFq2c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Toc2lEPTB;MD6wOFAyOSEQvF2=	NEfBXZhUSU6JRWK=
SW1710	NXvM[GIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDHTWM2OD1yLkC0NFE5KM7:TR?=	NULkUolGW0GQR1XS
HuP-T4	NIHnbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vy[2lEPTB;MD6wOFEyQCEQvF2=	MmLxV2FPT0WU
LB373-MEL-D	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMESyN\|Ih\|ryP	MnmxV2FPT0WU
EW-13	M1zzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXTcYVKSzVyPUCuNFQ1ODZizszN	M2fBXXNCVkeHUh?=
HT-29	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTIZ2tqUUN3ME2wMlA1PDlizszN	NIXiOFJUSU6JRWK=
SCC-25	M{PoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXKVmhiUUN3ME2wMlA1PDl2IN88US=>	MoqzV2FPT0WU
REH	NX:1c\|RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\jPGlKSzVyPUCuNFQ3OzVizszN	NYjYcHRqW0GQR1XS
L-363	NXPvUlIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrZflBKSzVyPUCuNFQ3PzlizszN	NEjIdmhUSU6JRWK=
NCI-H1770	NEPhRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXCU3J[UUN3ME2wMlA1Pjl5IN88US=>	M1nDSHNCVkeHUh?=
CHL-1	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\TUZRMUUN3ME2wMlA1QDV5IN88US=>	NX7nfJR5W0GQR1XS
ES1	NH75fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMES4PFUh\|ryP	MmWwV2FPT0WU
SCC-15	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMES5NFIh\|ryP	M13IRnNCVkeHUh?=
MRK-nu-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLNTWM2OD1yLkC0PVM3KM7:TR?=	M2TpT3NCVkeHUh?=
PF-382	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDlTJp6UUN3ME2wMlA1QTN7IN88US=>	NVy3R21SW0GQR1XS
COLO-680N	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPkSWFKSzVyPUCuNFUxPDdizszN	NFPGfY1USU6JRWK=
LK-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTwTWM2OD1yLkC1NFY{KM7:TR?=	NFrISGVUSU6JRWK=
NCI-H2342	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrodIpKSzVyPUCuNFUyOTdizszN	MkXQV2FPT0WU
HMV-II	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXGeHkxUUN3ME2wMlA2OjN7IN88US=>	NYDSW5BxW0GQR1XS
PC-14	M3nKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XlO2lEPTB;MD6wOVI2OiEQvF2=	M1vpXHNCVkeHUh?=
COLO-320-HSR	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMEWyPFkh\|ryP	MlntV2FPT0WU
697	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMEWzNlMh\|ryP	MkjHV2FPT0WU
NEC8	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUW0WJRIUUN3ME2wMlA2PTlizszN	MmPpV2FPT0WU
LCLC-97TM1	NHjL[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnlNXVKSzVyPUCuNFU2QTRizszN	NVy2UXZLW0GQR1XS
Daoy	M4q4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonPTWM2OD1yLkC1OlE3KM7:TR?=	M1PlT3NCVkeHUh?=
ETK-1	NXHvZmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fMbmlEPTB;MD6wOVY4OiEQvF2=	MUfTRW5ITVJ?
A388	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XoOmlEPTB;MD6wOVY6PSEQvF2=	NGjwSGJUSU6JRWK=
COLO-205	NHTFRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX2TWM2OD1yLkC1O\|E3KM7:TR?=	NXPMVWluW0GQR1XS
SK-PN-DW	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTqTWM2OD1yLkC1O\|I6KM7:TR?=	NVXGXWtrW0GQR1XS
SF268	NVPjflZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17qU2lEPTB;MD6wOVc2PiEQvF2=	M{fTOXNCVkeHUh?=
OCI-AML2	NWLERpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIr3bFJKSzVyPUCuNFU4PzdizszN	M2r2U3NCVkeHUh?=
GAMG	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC1WJJSUUN3ME2wMlA2QCEQvF2=	M3vHbnNCVkeHUh?=
BCPAP	M3zLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjYTWM2OD1yLkC1PFkzKM7:TR?=	NXfLZWdDW0GQR1XS
BC-1	M2XNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwME[wNlIh\|ryP	M3jQWHNCVkeHUh?=
IA-LM	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\HTWM2OD1yLkC2NFU{KM7:TR?=	NW\k[3ZZW0GQR1XS
NCI-H1299	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIn0UGdKSzVyPUCuNFYyOyEQvF2=	NVTleZJGW0GQR1XS
COR-L23	NUnEU2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULETHBNUUN3ME2wMlA3OTN2IN88US=>	MYPTRW5ITVJ?
KYSE-180	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPvdo9KSzVyPUCuNFYyPDJizszN	NWTKfYR7W0GQR1XS
LOXIMVI	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LGTWlEPTB;MD6wOlE5QCEQvF2=	NFiwXW1USU6JRWK=
BL-41	NXXLZXZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\ONGZKSzVyPUCuNFYzOTlizszN	MkfqV2FPT0WU
BL-70	NHfSXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVe4fIRTUUN3ME2wMlA3OzB{IN88US=>	NXzicphRW0GQR1XS
NOS-1	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwME[0NVEh\|ryP	MmjjV2FPT0WU
NB13	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFG1VYdKSzVyPUCuNFY1OjFizszN	MYjTRW5ITVJ?
CAL-27	Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwME[0OlQh\|ryP	Mn;BV2FPT0WU
CA46	NHH2RWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPhbHdKSzVyPUCuNFY2OzdizszN	NWC2VnBsW0GQR1XS
SW962	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L6d2lEPTB;MD6wOlU3QSEQvF2=	NYTFdJBvW0GQR1XS
NCI-H226	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwME[2N\|Ih\|ryP	NXjtcphXW0GQR1XS
KYSE-70	NWj0OnF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:0UWlEPTB;MD6wOlk1PSEQvF2=	MnnmV2FPT0WU
Daudi	Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PkNmlEPTB;MD6wO\|A5OSEQvF2=	NXLGOGtkW0GQR1XS
SW626	NVL5WHN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMEeyNFQh\|ryP	NF7NRXdUSU6JRWK=
ESS-1	M1nwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\aUWdiUUN3ME2wMlA4OjR4IN88US=>	M4LsO3NCVkeHUh?=
YT	NGPLWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT0TWM2OD1yLkC3N\|Q2KM7:TR?=	NGjlWWJUSU6JRWK=
P12-ICHIKAWA	M1XkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H1NWlEPTB;MD6wO\|M1QSEQvF2=	Mnv1V2FPT0WU
BxPC-3	NHL5W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTvTWM2OD1yLkC3OFU5KM7:TR?=	NWqyPWxDW0GQR1XS
CTV-1	NV3TbokxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIP2W5hKSzVyPUCuNFc2OTdizszN	M3fofXNCVkeHUh?=
MLMA	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7tco41UUN3ME2wMlA4PTN2IN88US=>	MkK2V2FPT0WU
WSU-NHL	NGP6TGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfJfpJKSzVyPUCuNFc2PTRizszN	MljuV2FPT0WU
CTB-1	NELBR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEe1PFgh\|ryP	MX7TRW5ITVJ?
MMAC-SF	NFfuZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEe2Olgh\|ryP	NWDZPIlxW0GQR1XS
8-MG-BA	NGG3SHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlWwTWM2OD1yLkC3PFAyKM7:TR?=	M3;G[nNCVkeHUh?=
NCI-H358	NXXh[o9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K3[2lEPTB;MD6wO\|g4QSEQvF2=	NYfoSVFDW0GQR1XS
BFTC-905	M4Tje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULscWRmUUN3ME2wMlA4QTB7IN88US=>	NYG1PG9NW0GQR1XS
NCI-H727	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jkUWlEPTB;MD6wPFA2OyEQvF2=	MV3TRW5ITVJ?
CHP-212	NX;zbZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXRTWM2OD1yLkC4NFk2KM7:TR?=	M4\ocnNCVkeHUh?=
HOP-62	M3jBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\XVGlEPTB;MD6wPFI1PSEQvF2=	NVHjV\|BCW0GQR1XS
CESS	M{XYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPUTWM2OD1yLkC4NlY6KM7:TR?=	Mo\FV2FPT0WU
HuCCT1	M2X2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMEizN\|Mh\|ryP	MYjTRW5ITVJ?
DEL	NETBcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLIT4ZMUUN3ME2wMlA5OzR5IN88US=>	MkfXV2FPT0WU
5637	NYfPfZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnzTlRKSzVyPUCuNFg{PjdizszN	M4\oW3NCVkeHUh?=
RS4-11	M4fiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLpTWM2OD1yLkC4OFk4KM7:TR?=	NIm3dnNUSU6JRWK=
KURAMOCHI	NFvMTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvuTWM2OD1yLkC4OVA6KM7:TR?=	NUjuZVZ2W0GQR1XS
A427	Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEi1NVIh\|ryP	MlTOV2FPT0WU
A3-KAW	NVuxXG54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHVUGdKSzVyPUCuNFg2PjZizszN	NHnGT2dUSU6JRWK=
LS-123	NXmxWWk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfD[IRKSzVyPUCuNFg4OTlizszN	MoP2V2FPT0WU
LoVo	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILDXWZKSzVyPUCuNFg4OiEQvF2=	MWDTRW5ITVJ?
PA-1	NI\MeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknzTWM2OD1yLkC4O\|Y6KM7:TR?=	NGnSN\|lUSU6JRWK=
CP50-MEL-B	NY\GVWR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrrdZJlUUN3ME2wMlA5Pzl\|IN88US=>	MWrTRW5ITVJ?
A431	M4rDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mle5TWM2OD1yLkC4PFAyKM7:TR?=	MoLDV2FPT0WU
HCT-116	NHPIfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn6Z\|NKSzVyPUCuNFg5ODJizszN	MlzVV2FPT0WU
A4-Fuk	NE\0T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jSZWlEPTB;MD6wPFk1PyEQvF2=	MVzTRW5ITVJ?
RPMI-6666	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PYV2lEPTB;MD6wPFk3PyEQvF2=	MmLSV2FPT0WU
Calu-6	NFGw[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3RTWM2OD1yLkC5NFI6KM7:TR?=	M2rnXXNCVkeHUh?=
KMOE-2	NYXsUIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[3clBxUUN3ME2wMlA6ODN7IN88US=>	NIToSI5USU6JRWK=
A704	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT2dGxKSzVyPUCuNFkyPSEQvF2=	M4X3WHNCVkeHUh?=
HO-1-N-1	M2TVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nFZWlEPTB;MD6wPVI1QSEQvF2=	Mof6V2FPT0WU
NCI-H2122	NUHqfXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jKO2lEPTB;MD6wPVM4QCEQvF2=	Mkm3V2FPT0WU
U-698-M	M1T4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofSTWM2OD1yLkC5OFA6KM7:TR?=	M4TNS3NCVkeHUh?=
IST-SL2	M2jF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\yRmlEPTB;MD6wPVQ3QCEQvF2=	NH7wR5RUSU6JRWK=
TE-10	M{CxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljaTWM2OD1yLkC5OVg1KM7:TR?=	NUHPNJpIW0GQR1XS
PANC-03-27	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLS[FUxUUN3ME2wMlA6PjdzIN88US=>	MlHYV2FPT0WU
KYSE-410	NF\qcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:2SWlEPTB;MD6wPVc6PyEQvF2=	NW\S[3VNW0GQR1XS
TE-8	M1Pp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXi0dWU5UUN3ME2wMlA6QDh3IN88US=>	NH7ZfolUSU6JRWK=
MN-60	NITXOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7PTWM2OD1yLkC5PFk4KM7:TR?=	MVTTRW5ITVJ?
NCI-H460	NWTDUmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XBT2lEPTB;MD6xNFA6KM7:TR?=	NX\NSodyW0GQR1XS
LB771-HNC	NX3xVWlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPnUZFKSzVyPUCuNVAzPTVizszN	NX7XTGVLW0GQR1XS
ES4	NH3yN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMUCyOlQh\|ryP	MmDHV2FPT0WU
HUTU-80	M{fkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMUCzOlUh\|ryP	MmHUV2FPT0WU
647-V	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jZZWlEPTB;MD6xNFQxQCEQvF2=	NG\0eYNUSU6JRWK=
HTC-C3	NWDHS4J[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrFfJZKSzVyPUCuNVA1OzJizszN	NYXTXXVUW0GQR1XS
NTERA-S-cl-D1	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DIWGlEPTB;MD6xNFQ1QCEQvF2=	NGXWZXFUSU6JRWK=
A2058	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELWcmhKSzVyPUCuNVA3PTVizszN	MmnUV2FPT0WU
MZ1-PC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGSzS4JKSzVyPUCuNVA5OyEQvF2=	NXvITHpiW0GQR1XS
J82	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDBTWM2OD1yLkGwPFg1KM7:TR?=	NGPUNmNUSU6JRWK=
ARH-77	NEDsW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMUGg{txO	NGfMVGtUSU6JRWK=
Ca9-22	NIfJTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljLTWM2OD1yLkGxNVI5KM7:TR?=	NVHjbHlQW0GQR1XS
NCI-H1648	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMUGyPFYh\|ryP	M2PsbnNCVkeHUh?=
MC116	NUjyb456T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMUGzN\|ch\|ryP	NXPRZllYW0GQR1XS
EoL-1-cell	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzxZWRqUUN3ME2wMlEyPDZ5IN88US=>	NGTUOFZUSU6JRWK=
PANC-10-05	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH6TWM2OD1yLkGxOFkyKM7:TR?=	M3HYcnNCVkeHUh?=
SF539	NUXZTGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWH4UZJWUUN3ME2wMlEyPjF4IN88US=>	NELpdHlUSU6JRWK=
ES8	M1PJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDWUZZKSzVyPUCuNVE3OzNizszN	MWHTRW5ITVJ?
NCI-H810	NHn3[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXGT\|V4UUN3ME2wMlEyPjZ2IN88US=>	M1XsUnNCVkeHUh?=
J-RT3-T3-5	M4SyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXG[ZhKSzVyPUCuNVE4PSEQvF2=	MlrHV2FPT0WU
NY	M4LCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTaZmN2UUN3ME2wMlEyQDF5IN88US=>	M3S5Z3NCVkeHUh?=
NCI-SNU-1	NHPMOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFroSlFKSzVyPUCuNVIyPDhizszN	M4j4NHNCVkeHUh?=
EFM-19	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nvXWlEPTB;MD6xNlM4PCEQvF2=	NWi4b4xzW0GQR1XS
HCC1806	NFzYbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMUKzPFMh\|ryP	NUPCSoFbW0GQR1XS
HCE-T	M4\6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkW1TWM2OD1yLkGyOVMyKM7:TR?=	NEPLTnNUSU6JRWK=
HT-1376	M1j2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTBZ4ZKSzVyPUCuNVI3PjhizszN	NH3ZWlBUSU6JRWK=
BE-13	NFvMXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3joN2lEPTB;MD6xNlg3PiEQvF2=	MW\TRW5ITVJ?
NCI-H520	M3XFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjpPFJKSzVyPUCuNVI5PjdizszN	M3vrdnNCVkeHUh?=
SK-MES-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX2NGVKSzVyPUCuNVI6OTNizszN	MUXTRW5ITVJ?
SNU-423	NH;GdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWToWGI{UUN3ME2wMlEzQTF2IN88US=>	NWDHUGJOW0GQR1XS
Ramos-2G6-4C10	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMUK5NVYh\|ryP	NY[xdm5bW0GQR1XS
EW-18	NF;NOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMUOwNlYh\|ryP	MoS5V2FPT0WU
NCI-H2087	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnXbGZ{UUN3ME2wMlE{ODJ5IN88US=>	Mm\PV2FPT0WU
COLO-792	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMUOxOlUh\|ryP	MYrTRW5ITVJ?
QIMR-WIL	M3izRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfFRXFKSzVyPUCuNVMzOjNizszN	NXuzTWVoW0GQR1XS
ACHN	NFu1OHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXrRnZKSzVyPUCuNVMzPDdizszN	MXzTRW5ITVJ?
RPMI-8866	NFTSPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzVdYZKSzVyPUCuNVMzPjFizszN	M1LLbHNCVkeHUh?=
SK-LU-1	M{LMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMUO0OFkh\|ryP	NYPBPHJKW0GQR1XS
SK-UT-1	NUDYN2tET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnqUFlWUUN3ME2wMlE{PjJ6IN88US=>	NXLJO3NqW0GQR1XS
MFE-296	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjwTWM2OD1yLkGzPFY1KM7:TR?=	M3\BfXNCVkeHUh?=
RD	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fRe2lEPTB;MD6xN\|k6PyEQvF2=	MWLTRW5ITVJ?
LS-411N	NXzCNVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3sTWM2OD1yLkG0Nlk2KM7:TR?=	M2GwdHNCVkeHUh?=
NCI-H747	NFi0[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn3SXRKSzVyPUCuNVQ{KM7:TR?=	MluyV2FPT0WU
ES6	M2CzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXz6Sm5YUUN3ME2wMlE1OzZizszN	NFfU[VVUSU6JRWK=
TE-1	M1ywfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnMTWM2OD1yLkG0OFA4KM7:TR?=	NHrQWnZUSU6JRWK=
SJSA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn6TWM2OD1yLkG0O\|A4KM7:TR?=	NHjHZVdUSU6JRWK=
NCI-H1355	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMUWyPVMh\|ryP	MmT1V2FPT0WU
HEL	M2rzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPPTWM2OD1yLkG1OFQ4KM7:TR?=	MWHTRW5ITVJ?
639-V	NGH4fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD3TWM2OD1yLkG1OVk3KM7:TR?=	NX\0bXJNW0GQR1XS
AN3-CA	NX31UIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnkTWM2OD1yLkG1OlM6KM7:TR?=	MV;TRW5ITVJ?
SK-MEL-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU[2VnlIUUN3ME2wMlE2PjZ6IN88US=>	NYHBXFZpW0GQR1XS
SW872	NITZfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTz[FBkUUN3ME2wMlE3ODR{IN88US=>	MofHV2FPT0WU
DU-4475	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHMTWM2OD1yLkG2NVYzKM7:TR?=	MVHTRW5ITVJ?
YKG-1	NV\L[YxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\ITWM2OD1yLkG2Nlc{KM7:TR?=	MoSwV2FPT0WU
GT3TKB	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvETYFKSzVyPUCuNVYzQDNizszN	NFfuS4hUSU6JRWK=
GB-1	NWPwVpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX23e3M5UUN3ME2wMlE3PDJ2IN88US=>	M1zjUnNCVkeHUh?=
KARPAS-422	M4XJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDIbHNmUUN3ME2wMlE3PTd2IN88US=>	MmLnV2FPT0WU
ATN-1	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\ld2lEPTB;MD6xOlY2PiEQvF2=	MXrTRW5ITVJ?
HLE	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYCxXmNCUUN3ME2wMlE3QDd5IN88US=>	M17ySXNCVkeHUh?=
D-542MG	M{e0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDmWZk4UUN3ME2wMlE3QTh4IN88US=>	MWPTRW5ITVJ?
EB-3	NFnU[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLvTWM2OD1yLkG3N\|Eh\|ryP	Ml\6V2FPT0WU
HCC1143	NWLZXWFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4m1d2lEPTB;MD6xO\|M6PiEQvF2=	MVHTRW5ITVJ?
DJM-1	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTlTWM2OD1yLkG3OFUyKM7:TR?=	NHzjRoxUSU6JRWK=
BT-474	NXnncnlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPh[nJKSzVyPUCuNVc1QDlizszN	M4LRRnNCVkeHUh?=
BB65-RCC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjMTWM2OD1yLkG3OVQ2KM7:TR?=	NIrUSlBUSU6JRWK=
NCI-H292	NH23OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMUe2NFEh\|ryP	Mn3TV2FPT0WU
MKN28	NULuVFMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHxXlVKSzVyPUCuNVc3PTNizszN	MXHTRW5ITVJ?
TK10	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXCOnRUUUN3ME2wMlE4PzB{IN88US=>	MXPTRW5ITVJ?
TYK-nu	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4H5fmlEPTB;MD6xO\|k1QSEQvF2=	NHfqUY9USU6JRWK=
8305C	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1T5bmlEPTB;MD6xO\|k4OSEQvF2=	M1n2XHNCVkeHUh?=
MV-4-11	M{\HXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17jfGlEPTB;MD6xO\|k4PyEQvF2=	NXPlW5ZzW0GQR1XS
NCI-H522	M4nOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkH5TWM2OD1yLkG4NFk1KM7:TR?=	MYDTRW5ITVJ?
Hs-578-T	NIDUelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVS2UJhqUUN3ME2wMlE5Ojl{IN88US=>	M2f3S3NCVkeHUh?=
LCLC-103H	NHrOSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfOW5dKSzVyPUCuNVg2OjdizszN	MYjTRW5ITVJ?
MHH-ES-1	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPCbZFKSzVyPUCuNVg3OjlizszN	NYfuZ25WW0GQR1XS
NCI-H441	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUmxOFgh\|ryP	MlW5V2FPT0WU
AM-38	M3;Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULHblJYUUN3ME2wMlE6OjJ3IN88US=>	MWfTRW5ITVJ?
SW1783	NYiwOoxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fzPGlEPTB;MD6xPVMxPSEQvF2=	MoThV2FPT0WU
SK-HEP-1	NFXLOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMUm2N\|ch\|ryP	NEjuOFVUSU6JRWK=
OAW-28	M3zqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoS2TWM2OD1yLkKwNVc5KM7:TR?=	MmPXV2FPT0WU
TE-15	M{P1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTGPYpQUUN3ME2wMlIxOjV{IN88US=>	NVHER\|lKW0GQR1XS
HCE-4	M37X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMkCyPFQh\|ryP	M4rtXnNCVkeHUh?=
JiyoyeP-2003	NEf1VmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrkdJVKSzVyPUCuNlA{OzZizszN	M2HMXXNCVkeHUh?=
OVCAR-4	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrTOJdKSzVyPUCuNlA3OjhizszN	M1XUcXNCVkeHUh?=
SNU-449	NG\oZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHntfZdKSzVyPUCuNlA4QTdizszN	NWLxdm97W0GQR1XS
SBC-5	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMkGyNVUh\|ryP	NIPx[2JUSU6JRWK=
T84	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fCN2lEPTB;MD6yNVI1QCEQvF2=	NFvBe3pUSU6JRWK=
LP-1	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\mRplRUUN3ME2wMlIyOzB{IN88US=>	NIPYdlJUSU6JRWK=
MG-63	NFzZfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfITpJ1UUN3ME2wMlIyOzh{IN88US=>	MkXMV2FPT0WU
OAW-42	NIH0[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vjcGlEPTB;MD6yNVQ4QCEQvF2=	M2XDfXNCVkeHUh?=
L-540	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7TOmV[UUN3ME2wMlIyPTl6IN88US=>	MXTTRW5ITVJ?
RH-1	Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMkKyOFIh\|ryP	Ml;UV2FPT0WU
HCT-15	M3HzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWWzfFd1UUN3ME2wMlIzPDh2IN88US=>	M{jRR3NCVkeHUh?=
OCUB-M	M4nROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMkK0PFgh\|ryP	NI\CcmNUSU6JRWK=
GP5d	NWHKUGhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nGVGlEPTB;MD6yNlUzQCEQvF2=	MlLVV2FPT0WU
NCI-H2030	NUjh[\|lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonJTWM2OD1yLkKyO\|M1KM7:TR?=	M2TpSnNCVkeHUh?=
ML-2	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vJWmlEPTB;MD6yNlg5QSEQvF2=	M1nHRXNCVkeHUh?=
CAL-39	NG[zTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\QeHFKSzVyPUCuNlI6OzZizszN	M17CfnNCVkeHUh?=
MIA-PaCa-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTUT\|BKSzVyPUCuNlMzQDdizszN	NW\tWnJ3W0GQR1XS
TE-9	M2nZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYL1PW12UUN3ME2wMlI{OzJizszN	M{HnWXNCVkeHUh?=
LB2518-MEL	M4WxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUW1SWJ2UUN3ME2wMlI{Ozd{IN88US=>	M4jTR3NCVkeHUh?=
DB	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYK3dnFbUUN3ME2wMlI{PDN6IN88US=>	NYqwelVMW0GQR1XS
NCI-H596	M1X1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnzVG8xUUN3ME2wMlI{PTdzIN88US=>	NEns[Y9USU6JRWK=
SW1990	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTuSoUzUUN3ME2wMlI{QTR4IN88US=>	M2\0PXNCVkeHUh?=
P30-OHK	NVrhUppYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\OWWtKSzVyPUCuNlQxPSEQvF2=	NH;m[ppUSU6JRWK=
ALL-PO	M1vTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTQfYZKSzVyPUCuNlQyPjlizszN	NIXybW5USU6JRWK=
Saos-2	NF\B[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXaTWM2OD1yLkK0OVcyKM7:TR?=	MVfTRW5ITVJ?
MFH-ino	NWK1dGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTadVdKSzVyPUCuNlQ3QTJizszN	M2TWRnNCVkeHUh?=
OE33	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\iXoluUUN3ME2wMlI2OTFizszN	NWLkcW9NW0GQR1XS
Calu-3	NV;EUGhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMkWyPVch\|ryP	MXPTRW5ITVJ?
HT	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMkW2NlEh\|ryP	NHfSOmJUSU6JRWK=
LXF-289	NXG5eIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\me4lVUUN3ME2wMlI2QTh2IN88US=>	Mm\VV2FPT0WU
KGN	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG1dXdyUUN3ME2wMlI3ODh7IN88US=>	MV3TRW5ITVJ?
NCI-H1417	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3kdWRKSzVyPUCuNlY2OjRizszN	MoK2V2FPT0WU
SF126	NVHtTGlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm1XWF6UUN3ME2wMlI4OzB{IN88US=>	Mn\3V2FPT0WU
SAS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr3O5NKSzVyPUCuNlc{ODhizszN	M1v2SHNCVkeHUh?=
22RV1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPVTWM2OD1yLkK3N\|c5KM7:TR?=	NI\sT2RUSU6JRWK=
GI-1	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LyZ2lEPTB;MD6yO\|Q5PyEQvF2=	MXHTRW5ITVJ?
ES3	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvSTWM2OD1yLkK3O\|Y{KM7:TR?=	NV[1c\|VVW0GQR1XS
NB1	M4HjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojlTWM2OD1yLkK3PFc3KM7:TR?=	NHrOPVRUSU6JRWK=
NCI-H650	NWO2XnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMkizNFIh\|ryP	MV;TRW5ITVJ?
IST-MES1	NX7ad5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1K4WWlEPTB;MD6yPFU2PCEQvF2=	MWTTRW5ITVJ?
UM-UC-3	NWXhOJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nrdmlEPTB;MD6yPVE1KM7:TR?=	NIH4fVJUSU6JRWK=
CAL-120	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[4TWM2OD1yLkK5OlMyKM7:TR?=	MVrTRW5ITVJ?
UACC-62	NIPLPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGOy[mJKSzVyPUCuN\|AzPDFizszN	NF24botUSU6JRWK=
TE-11	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7ycVZKSzVyPUCuN\|AzPDlizszN	M1;vVXNCVkeHUh?=
MKN1	M3f0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVz2U4JYUUN3ME2wMlMxOzZizszN	NEDMWpNUSU6JRWK=
KS-1	Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2SzVmlEPTB;MD6zNFUzPiEQvF2=	NHLMZ3pUSU6JRWK=
GCIY	NH7aUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEWweFdKSzVyPUCuN\|ExODJizszN	MWDTRW5ITVJ?
OVCAR-5	NFrVN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLBTWM2OD1yLkOxNVA3KM7:TR?=	M2jmeHNCVkeHUh?=
U-266	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL5O3BzUUN3ME2wMlMyOTR5IN88US=>	MXzTRW5ITVJ?
Calu-1	Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzlXllJUUN3ME2wMlMyOjh7IN88US=>	NXfHTYFKW0GQR1XS
SK-LMS-1	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwM{G0Nlkh\|ryP	MU\TRW5ITVJ?
COLO-741	M4\xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnS[XBKSzVyPUCuN\|E3OTRizszN	MmDNV2FPT0WU
RPMI-8226	NXfQTlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHRRnhKSzVyPUCuN\|E3PDFizszN	M2XaTnNCVkeHUh?=
KM12	NGrm[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rMNWlEPTB;MD6zNVg{KM7:TR?=	NViyVFZzW0GQR1XS
NMC-G1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PJUWlEPTB;MD6zNVg3KM7:TR?=	NEjUbZlUSU6JRWK=
SJRH30	MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm5TWM2OD1yLkOyNFUzKM7:TR?=	MV\TRW5ITVJ?
COR-L105	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\hTHBrUUN3ME2wMlMzOjF6IN88US=>	NF7FTZJUSU6JRWK=
IM-9	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXTTWM2OD1yLkOzNFIyKM7:TR?=	M2ryPXNCVkeHUh?=
TE-12	NXLMOJNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz3SmMzUUN3ME2wMlM{OzF5IN88US=>	MlTJV2FPT0WU
KG-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[xTWM2OD1yLkOzOFMzKM7:TR?=	MkHPV2FPT0WU
U251	NVG2PYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fHcWlEPTB;MD6zN\|Q2PiEQvF2=	M2Ljc3NCVkeHUh?=
EFO-27	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTxU2ZKSzVyPUCuN\|M6PTFizszN	NX\vXZQyW0GQR1XS
EW-24	NUK4VnQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;wdJkzUUN3ME2wMlM{QTh2IN88US=>	Mn7NV2FPT0WU
SF295	NHnyc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH2TWM2OD1yLkOzPVk6KM7:TR?=	M4qzXnNCVkeHUh?=
MC-IXC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHjUIRYUUN3ME2wMlM1PSEQvF2=	MX;TRW5ITVJ?
NCI-H2405	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mly1TWM2OD1yLkO0O\|MzKM7:TR?=	MWLTRW5ITVJ?
NCI-H2009	M{e1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXMflBKSzVyPUCuN\|Q4OzlizszN	NFzOc3BUSU6JRWK=
LB1047-RCC	M4HPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn61TWM2OD1yLkO1PFE2KM7:TR?=	MkPIV2FPT0WU
KNS-81-FD	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnJcHdKSzVyPUCuN\|Y3PjdizszN	NXTXTYxLW0GQR1XS
HOP-92	NYHtelYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUn1VXNEUUN3ME2wMlM3QDNizszN	MYjTRW5ITVJ?
L-428	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TkPGlEPTB;MD6zO\|AyPiEQvF2=	MXHTRW5ITVJ?
C3A	NUf5RnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTtOHU3UUN3ME2wMlM4Ozd7IN88US=>	NGDpc29USU6JRWK=
NCI-H1792	NGL2PGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;mcFgzUUN3ME2wMlM4PjV3IN88US=>	NUDQOYp3W0GQR1XS
HuH-7	M3TvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoW1TWM2OD1yLkO3PVEh\|ryP	Mni1V2FPT0WU
AGS	NIXjZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1WydGlEPTB;MD6zPFY{QCEQvF2=	NUmyZ\|RzW0GQR1XS
HT-1197	M1H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Lo[mlEPTB;MD6zPVQ3KM7:TR?=	MUnTRW5ITVJ?
CGTH-W-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\YTWM2OD1yLkO5PVE{KM7:TR?=	MVLTRW5ITVJ?
KNS-42	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoW3TWM2OD1yLkSwNFQ2KM7:TR?=	NFnNe\|FUSU6JRWK=
HuO-3N1	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwNECwOVUh\|ryP	NV[5OotuW0GQR1XS
VMRC-RCZ	M1zUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPFc45KSzVyPUCuOFA{ODNizszN	MkTvV2FPT0WU
SW954	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnZRoVzUUN3ME2wMlQxOzN3IN88US=>	NWP4emlbW0GQR1XS
MES-SA	NFXQUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHlTWM2OD1yLkSwOVA2KM7:TR?=	M1npe3NCVkeHUh?=
Ca-Ski	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7pOoFkUUN3ME2wMlQxPTJ2IN88US=>	NVLXdIFbW0GQR1XS
SW13	M4K0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1K2PWlEPTB;MD60NFYzPiEQvF2=	NU\mWXNVW0GQR1XS
NCI-H1437	NXjlc3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX76eGlKUUN3ME2wMlQxQDB3IN88US=>	NF60SppUSU6JRWK=
U-118-MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXLSYxKSzVyPUCuOFA6ODRizszN	NVuwNnRTW0GQR1XS
NCI-H1734	NUK0UYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MomwTWM2OD1yLkSyNFE{KM7:TR?=	MV3TRW5ITVJ?
HDLM-2	NU\mdGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfSOYhKSzVyPUCuOFIxOzNizszN	Mk\6V2FPT0WU
AU565	M3TaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwNEK0Olgh\|ryP	NGO1ZXFUSU6JRWK=
FADU	NWG0[pFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInrfW1KSzVyPUCuOFI3PDlizszN	M3e5UHNCVkeHUh?=
OS-RC-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjMTWM2OD1yLkSzNFg{KM7:TR?=	MoGxV2FPT0WU
CAMA-1	MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;xTYpxUUN3ME2wMlQ{PjJ4IN88US=>	M170ZnNCVkeHUh?=
MONO-MAC-6	M2HS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXv0em5bUUN3ME2wMlQ{QDR7IN88US=>	MonKV2FPT0WU
LB831-BLC	NYr1UW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHVWY52UUN3ME2wMlQ1OzdzIN88US=>	MX;TRW5ITVJ?
SW982	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfOXFVjUUN3ME2wMlQ1PTJ6IN88US=>	NFHkbZpUSU6JRWK=
SCC-3	NXPOVoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XzXGlEPTB;MD60OFU4QSEQvF2=	MnHrV2FPT0WU
C32	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjUO45KSzVyPUCuOFUzOjlizszN	NH\5[IRUSU6JRWK=
BFTC-909	NXfVS2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D2eWlEPTB;MD60OVI6QSEQvF2=	NXHWZmMzW0GQR1XS
MEG-01	NHPEb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7vTWM2OD1yLkS1N\|c{KM7:TR?=	MVzTRW5ITVJ?
M14	NXzVT4llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;1TWM2OD1yLkS1PVc6KM7:TR?=	MkLEV2FPT0WU
MPP-89	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz4RmZKSzVyPUCuOFYzPTZizszN	M{\pdnNCVkeHUh?=
HCC1937	NGjFe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwNE[zPFQh\|ryP	MlixV2FPT0WU
SW837	NYPNOZJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwNE[3NlIh\|ryP	NEX5cJpUSU6JRWK=
DU-145	M{HYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHZTlZ6UUN3ME2wMlQ3PzJ7IN88US=>	MYXTRW5ITVJ?
LB996-RCC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHWUGR7UUN3ME2wMlQ4ODV2IN88US=>	NYDYW5dRW0GQR1XS
C8166	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jlVWlEPTB;MD60O\|Qh\|ryP	M2TzRnNCVkeHUh?=
MOLT-4	NIXGNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O0XGlEPTB;MD60O\|c{PCEQvF2=	NYnEWG1SW0GQR1XS
DMS-53	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXNXnZKSzVyPUCuOFc5ODlizszN	M{nES3NCVkeHUh?=
TE-5	NFjXdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT5[Ih7UUN3ME2wMlQ5OzB3IN88US=>	NXnBV3cxW0GQR1XS
KYSE-520	NGO5W4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4CySWlEPTB;MD60PFM1OyEQvF2=	MV7TRW5ITVJ?
Detroit562	MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jQRmlEPTB;MD60PFg3KM7:TR?=	NYnBc4V3W0GQR1XS
SIMA	NG[1VmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwNEm0NVch\|ryP	M3HaenNCVkeHUh?=
NCI-H1651	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLmTWM2OD1yLkS5Olch\|ryP	MWXTRW5ITVJ?
HCC1599	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;hTWM2OD1yLkS5PVU2KM7:TR?=	Mn7GV2FPT0WU
ABC-1	NWDuPZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIT4bpRKSzVyPUCuOVA1QTZizszN	MoLTV2FPT0WU
CAL-33	M3zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkSyTWM2OD1yLkWwPFQ1KM7:TR?=	MXfTRW5ITVJ?
OPM-2	M{PiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHVO4FKUUN3ME2wMlUxQTN5IN88US=>	M3HvWnNCVkeHUh?=
RPMI-7951	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT2Nm5KSzVyPUCuOVA6PTdizszN	MXTTRW5ITVJ?
HT-1080	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\aTWM2OD1yLkWxNVE6KM7:TR?=	NVzwTJBMW0GQR1XS
LC4-1	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTHU5ZQUUN3ME2wMlUyPDB\|IN88US=>	M4rNfnNCVkeHUh?=
OVCAR-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIH0WoJKSzVyPUCuOVE2PyEQvF2=	NEHFe29USU6JRWK=
CAPAN-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHS4OHBKSzVyPUCuOVIzQDhizszN	M4\JdXNCVkeHUh?=
SK-OV-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwNUK0N\|Qh\|ryP	MYnTRW5ITVJ?
HuP-T3	NVL2PY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEewRoRKSzVyPUCuOVI5OjdizszN	MlHBV2FPT0WU
NCI-H838	NFLTfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;STWM2OD1yLkWyPFQ6KM7:TR?=	M4q2W3NCVkeHUh?=
K5	NVLiRnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLLdJhKSzVyPUCuOVMzODFizszN	MWPTRW5ITVJ?
CAL-72	M4SxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwNUOzPFch\|ryP	MUXTRW5ITVJ?
NH-12	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDCTWM2OD1yLkWzPVU6KM7:TR?=	NEHlPYRUSU6JRWK=
SNB75	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\RUGlEPTB;MD61OVc{KM7:TR?=	NEnHU4JUSU6JRWK=
BPH-1	NXnRe\|Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVG4dpVqUUN3ME2wMlU3OzR2IN88US=>	M3u2WHNCVkeHUh?=
NOMO-1	NHK3bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnnTWM2OD1yLkW2N\|czKM7:TR?=	MUDTRW5ITVJ?
G-402	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2H2Z2lEPTB;MD61OlQ6QSEQvF2=	MmfMV2FPT0WU
NCI-H2052	NH\wS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwNU[3OFEh\|ryP	MmO0V2FPT0WU
RCM-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwNUexOlYh\|ryP	MlT4V2FPT0WU
COR-L279	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3vc4JxUUN3ME2wMlU4OTh3IN88US=>	MlTlV2FPT0WU
A253	M1W2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmqxTWM2OD1yLkW3OVI2KM7:TR?=	Mk[xV2FPT0WU
SK-MM-2	MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwNUe2O\|kh\|ryP	NXGwV2h5W0GQR1XS
NCI-H1703	NFPUflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwNUm0Nlch\|ryP	MUfTRW5ITVJ?
UACC-257	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrDdFVvUUN3ME2wMlU6PDh5IN88US=>	NYDHWXR5W0GQR1XS
KALS-1	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HvVGlEPTB;MD62NFAyOSEQvF2=	MUPTRW5ITVJ?
ES5	NInY[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwNkC0PEDPxE1?	MkH6V2FPT0WU
MHH-CALL-2	NW\qVWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwNkC4PFgh\|ryP	M1fFdXNCVkeHUh?=
ChaGo-K-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUW2SHNUUUN3ME2wMlYyOjJ7IN88US=>	NFPSdlBUSU6JRWK=
TGBC1TKB	M{f2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HCPGlEPTB;MD62NVk5KM7:TR?=	NUXDfnVGW0GQR1XS
KU-19-19	NWTFfnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rNZWlEPTB;MD62OFU5PiEQvF2=	MmLVV2FPT0WU
COLO-684	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PYemlEPTB;MD62OVYyOSEQvF2=	NYHQdnNVW0GQR1XS
LS-1034	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;md5RKSzVyPUCuOlU5OTlizszN	M2XGOXNCVkeHUh?=
RT-112	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHOTWM2OD1yLk[2OVg4KM7:TR?=	M4jIOnNCVkeHUh?=
Capan-2	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fN[mlEPTB;MD62OlYzOiEQvF2=	NU\LcYVlW0GQR1XS
HSC-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jkOmlEPTB;MD62OlY6QCEQvF2=	NU\jUFVJW0GQR1XS
COLO-824	NHyye29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf4RVhKSzVyPUCuOlc5OjNizszN	NYPnb\|JPW0GQR1XS
NCI-H2170	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwNkiyOVgh\|ryP	NHzhT5FUSU6JRWK=
GDM-1	NG\Zc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzrTWM2OD1yLk[4OFk1KM7:TR?=	MkPkV2FPT0WU
KP-4	NVP4XGVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jwVWlEPTB;MD62PVU4OyEQvF2=	NXzRcXZyW0GQR1XS
VA-ES-BJ	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moe5TWM2OD1yLk[5PVg3KM7:TR?=	M4[wPXNCVkeHUh?=
KM-H2	NFLHVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1j0W2lEPTB;MD63NFA6OSEQvF2=	NITWWGNUSU6JRWK=
HH	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXBb\|FKSzVyPUCuO\|A3PjJizszN	NFGx[WdUSU6JRWK=
DK-MG	NEPJNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwN{GwNVYh\|ryP	NVHtW49kW0GQR1XS
VM-CUB-1	NIS1bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwN{GyOVkh\|ryP	MUTTRW5ITVJ?
COLO-829	NXPnfIZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PyZWlEPTB;MD63NVk5PSEQvF2=	MUXTRW5ITVJ?
OMC-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHUOpdKSzVyPUCuO\|IyODRizszN	M4ewe3NCVkeHUh?=
NB12	NIDrO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofMTWM2OD1yLkeyOVA1KM7:TR?=	MoCyV2FPT0WU
NCI-H28	NHPL[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwN{SwPFMh\|ryP	NXLHTWdiW0GQR1XS
A673	NIfEO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3nTWM2OD1yLke1NVc4KM7:TR?=	M{SxXXNCVkeHUh?=
LB2241-RCC	NGjjflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDjOFc4UUN3ME2wMlc3ODh5IN88US=>	NHW0U3pUSU6JRWK=
CCRF-CEM	NVnyOo5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PNUGlEPTB;MD63O\|A2OiEQvF2=	Mn3UV2FPT0WU
NCI-H510A	NFfhbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHs[\|YzUUN3ME2wMlc4OTh4IN88US=>	NXzrcoZbW0GQR1XS
SW48	NX;5TmVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzQXGdbUUN3ME2wMlc4OzN\|IN88US=>	MVLTRW5ITVJ?
NCI-H2081	NGDJRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGmyRW5KSzVyPUCuO\|gyPDdizszN	NWjRNYVuW0GQR1XS
RMG-I	M4HuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIWwWFdKSzVyPUCuO\|gzOTJizszN	NV7CXZhOW0GQR1XS
LU-99A	M1X5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFmySGdKSzVyPUCuO\|g1OTNizszN	NHLqUmRUSU6JRWK=
KP-N-YS	NWXSSXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf0TWM2OD1yLke4PVIyKM7:TR?=	NV3Xbm5MW0GQR1XS
MDA-MB-231	NFfJclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37XNGlEPTB;MD64NFE{OSEQvF2=	MVvTRW5ITVJ?
U031	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zifGlEPTB;MD64NVQzOyEQvF2=	NYrmNJJzW0GQR1XS
EVSA-T	M4LUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYWzV\|M1UUN3ME2wMlgyPjd{IN88US=>	NHOxPG9USU6JRWK=
MDA-MB-157	M4rPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:zTWM2OD1yLkiyNlcyKM7:TR?=	MoXOV2FPT0WU
EHEB	NHvJc\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInYepFKSzVyPUCuPFIzPzZizszN	MoD0V2FPT0WU
KINGS-1	NEThSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwOEK1OVUh\|ryP	NH;O[VdUSU6JRWK=
23132-87	NHm5TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfDTWM2OD1yLkiyPFQ{KM7:TR?=	MVXTRW5ITVJ?
EFO-21	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PoWGlEPTB;MD64OFA5QSEQvF2=	NETBXlZUSU6JRWK=
DOK	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;4TWM2OD1yLki0PEDPxE1?	NGPURVlUSU6JRWK=
NCI-H2171	M4Lw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LFfGlEPTB;MD64OFk3KM7:TR?=	NXHm[Jl1W0GQR1XS
NCI-SNU-5	NH;uUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTuV4l[UUN3ME2wMlg2PTdizszN	MoH5V2FPT0WU
SK-N-DZ	NV3LRlNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj3TodJUUN3ME2wMlg2QTR\|IN88US=>	MYjTRW5ITVJ?
SNU-C2B	MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUm0Xm1rUUN3ME2wMlg3QDBzIN88US=>	NXXIdVZiW0GQR1XS
CP66-MEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwOEexNUDPxE1?	M4Lle3NCVkeHUh?=
SN12C	NIP5SXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jOWWlEPTB;MD64PFY{PyEQvF2=	NFuweYJUSU6JRWK=
A172	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHO4dFdKSzVyPUCuPFg3QThizszN	NIfkc\|NUSU6JRWK=
NCI-H2347	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwOEi3OVMh\|ryP	NIPjdI9USU6JRWK=
NCI-H2228	NYfBO\|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\uVZVKSzVyPUCuPFk{OzlizszN	M1PjdHNCVkeHUh?=
SNU-387	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwOUCyOlQh\|ryP	MVTTRW5ITVJ?
SK-MEL-24	M{XXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnNPYpKSzVyPUCuPVE{PDRizszN	Mn7EV2FPT0WU
MDA-MB-468	M4HlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwOUG3N{DPxE1?	MYHTRW5ITVJ?
NCI-H1694	MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXmWopKSzVyPUCuPVE5PzZizszN	Ml;kV2FPT0WU
CCF-STTG1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH0eWdSUUN3ME2wMlkzPjN5IN88US=>	MUDTRW5ITVJ?
K052	NWLUXINXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnwWoZKSzVyPUCuPVQxPDdizszN	M3va[3NCVkeHUh?=
NCI-H446	NELGdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3w[lNuUUN3ME2wMlk2ODFizszN	NGXaN2dUSU6JRWK=
MFE-280	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHUWVRKSzVyPUCuPVYzQTFizszN	MULTRW5ITVJ?
KU812	NY[yTJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIi4blZKSzVyPUCuPVk{QDlizszN	MUTTRW5ITVJ?
MDA-MB-361	NUjG[mVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH21S\|NKSzVyPUCuPVk4PzdizszN	MXnTRW5ITVJ?
Raji	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XMW2lEPTB;MT6wNlI3PyEQvF2=	MnX3V2FPT0WU
TE-6	NGPRdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKzRXJDUUN3ME2xMlA{PTZ4IN88US=>	MYnTRW5ITVJ?
CAL-148	M4fGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjJeXhKSzVyPUGuNFQ1PDNizszN	MXjTRW5ITVJ?
NCI-H1963	NFW5Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\kb2lEPTB;MT6wOFU2OyEQvF2=	NHzpfYZUSU6JRWK=
SK-N-AS	M4LWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\vc5hKSzVyPUGuNFQ3QDVizszN	MVXTRW5ITVJ?
RERF-LC-MS	M1;IWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFwME[zOFkh\|ryP	MnfvV2FPT0WU
BEN	NUTBNIh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPuTWM2OD1zLkC3NVM4KM7:TR?=	MmfuV2FPT0WU
CAS-1	M3vtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvqWGNDUUN3ME2xMlA6OTJ\|IN88US=>	MkDUV2FPT0WU
SW780	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFwMEmxPFEh\|ryP	NEe5UmNUSU6JRWK=
LU-65	M1f0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLP[G9KSzVyPUGuNFk1OSEQvF2=	MUHTRW5ITVJ?
D-283MED	NYfGWmJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\YR2lEPTB;MT6xNlI4OiEQvF2=	NVz0eHAxW0GQR1XS
HCC2157	NFnBVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXPTWM2OD1zLkGzOlQzKM7:TR?=	MYTTRW5ITVJ?
RCC10RGB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\2OIJuUUN3ME2xMlE1ODB4IN88US=>	Mm\5V2FPT0WU
PLC-PRF-5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;oTWM2OD1zLkG1NlI6KM7:TR?=	MXTTRW5ITVJ?
H4	NXzVVIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwMUW0N\|kh\|ryP	M2PQWnNCVkeHUh?=
TUR	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLoZVBiUUN3ME2xMlE2PzV{IN88US=>	NYmwdnc1W0GQR1XS
NCI-H2141	M3PhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV31d3ZIUUN3ME2xMlE5QTR4IN88US=>	NFTncZpUSU6JRWK=
PFSK-1	M2XYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLtdolKSzVyPUGuNlA2OzJizszN	NYDBTnNXW0GQR1XS
SK-MEL-28	NX3V[W5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\DRmh5UUN3ME2xMlI{OjJzIN88US=>	MUDTRW5ITVJ?
SCC-9	M1TtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\0[mlEPTB;MT6yN\|Y3PSEQvF2=	NWmwRWN4W0GQR1XS
T47D	NH3jXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fDfmlEPTB;MT6yN\|Y6PiEQvF2=	MYnTRW5ITVJ?
TCCSUP	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTFwMkWwNlkh\|ryP	M1PMfnNCVkeHUh?=
SU-DHL-1	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvuTWM2OD1zLkK1NVE5KM7:TR?=	NEnLOlJUSU6JRWK=
HL-60	M1y3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr1VlFKSzVyPUGuNlU2QDhizszN	NI\zWG5USU6JRWK=
NCI-H1436	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFL0Z\|ZKSzVyPUGuNlYyPDlizszN	NULzPWl6W0GQR1XS
DMS-114	NFLYVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUn3N4ZJUUN3ME2xMlI3PjN{IN88US=>	M3\tZnNCVkeHUh?=
BOKU	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTBTWM2OD1zLkK4NFk2KM7:TR?=	NHv0VFhUSU6JRWK=
MS-1	NVTLfnRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\mWZdzUUN3ME2xMlI6ODZ7IN88US=>	NHvQV3dUSU6JRWK=
NCI-H661	NXjDWFBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTFwM{C0O\|gh\|ryP	M1TtenNCVkeHUh?=
HT-3	NIW0VYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzkOHlKSzVyPUGuN\|A2OjlizszN	MnGwV2FPT0WU
CAL-54	NFr2XXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXuS21KSzVyPUGuN\|A4OjVizszN	Ml63V2FPT0WU
SW1463	M4L0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTFwM{G4O\|Ih\|ryP	NXi5NVBCW0GQR1XS
COLO-668	M3rDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HRSmlEPTB;MT6zN\|A2PiEQvF2=	M3\Wc3NCVkeHUh?=
PANC-08-13	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTFwM{O4NFMh\|ryP	MXPTRW5ITVJ?
BB49-HNC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTFwM{SwNUDPxE1?	NHryUIpUSU6JRWK=
M059J	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe0[o1KSzVyPUGuN\|U5OzJizszN	NY\uT2pNW0GQR1XS
NCCIT	M1HHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFwM{e5PFgh\|ryP	MoLRV2FPT0WU
LN-405	Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDUTWM2OD1zLkO5NlY1KM7:TR?=	Mo\qV2FPT0WU
UMC-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;hTWM2OD1zLkO5PVk3KM7:TR?=	NYru[ZBjW0GQR1XS
NB5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3juWWlEPTB;MT60NVIzPyEQvF2=	NVLkfoJbW0GQR1XS
TE-441-T	NInvR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTFwNEK4NVch\|ryP	MYTTRW5ITVJ?
ME-180	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFwNESzPVIh\|ryP	MY\TRW5ITVJ?
HCC70	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjPNG5WUUN3ME2xMlQ3ODl4IN88US=>	NVvPeVRUW0GQR1XS
no-10	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1m5NWlEPTB;MT60OlE5OSEQvF2=	MVXTRW5ITVJ?
JEG-3	NVK0SlluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33zXmlEPTB;MT61NFE{OiEQvF2=	NXnSPItHW0GQR1XS
no-11	M4\0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFwNUC4PFIh\|ryP	NYPDTlk4W0GQR1XS
CHP-126	M2HpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDMWWhKSzVyPUGuOVY3QTFizszN	MWLTRW5ITVJ?
EGI-1	NXuzc3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LFO2lEPTB;MT61PFAzPSEQvF2=	MVTTRW5ITVJ?
D-392MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fRS2lEPTB;MT61PVY{KM7:TR?=	M1zEO3NCVkeHUh?=
RT4	M4DWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO5XFRKSzVyPUGuOVk3OzdizszN	NVf2NG5DW0GQR1XS
A204	NU\DXIV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUC3[4dSUUN3ME2xMlU6QDBzIN88US=>	MWLTRW5ITVJ?
NCI-H1304	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTFwNkO1PVEh\|ryP	M1HYVnNCVkeHUh?=
Becker	M3PGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrwUndnUUN3ME2xMlY1OjRzIN88US=>	NXKyWIdkW0GQR1XS
OE19	NHThS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS1c5FKSzVyPUGuOlU2OThizszN	NXzscWgxW0GQR1XS
EKVX	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr2PXRSUUN3ME2xMlY2PjF6IN88US=>	MkPBV2FPT0WU
KLE	NUTZZlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjLdJZlUUN3ME2xMlY2PzF2IN88US=>	M2rDUXNCVkeHUh?=
K-562	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTFwNkewN\|ch\|ryP	NWfqXIhTW0GQR1XS
MDA-MB-175-VII	NHnYdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TlR2lEPTB;MT62PFk6PyEQvF2=	MonVV2FPT0WU
NCI-H716	NGPldopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml:0TWM2OD1zLk[5N\|A1KM7:TR?=	NVLmcVNUW0GQR1XS
Caov-3	NVj1XWUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXVPYZKSzVyPUGuOlk1OTNizszN	MVHTRW5ITVJ?
HCC1187	NIXrZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3PSJZTUUN3ME2xMlcxPTR3IN88US=>	MXXTRW5ITVJ?
CAKI-1	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DKXGlEPTB;MT63NlI6OiEQvF2=	NHvpdmtUSU6JRWK=
MOLT-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1znVmlEPTB;MT63N\|MxPyEQvF2=	NYrmcnlVW0GQR1XS
PC-3	NILaUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwN{WwPEDPxE1?	MoLUV2FPT0WU
DV-90	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3Wd2VKSzVyPUGuO\|U2QDVizszN	MVjTRW5ITVJ?
RXF393	NHjvOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwN{eyPVQh\|ryP	M4LkO3NCVkeHUh?=
SK-NEP-1	NWmzfI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTFwOEKzN\|kh\|ryP	M3PHeXNCVkeHUh?=
HCC1419	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4KyZWlEPTB;MT64NlY6OiEQvF2=	NYPncmJOW0GQR1XS
BV-173	NVzIc3VmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;PTWM2OD1zLkiyPVk2KM7:TR?=	Mn3IV2FPT0WU
MKN7	M32yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X1WmlEPTB;MT64PVIzKM7:TR?=	M3XGc3NCVkeHUh?=
LAN-6	M3TTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwOEm1OVMh\|ryP	NITDdYRUSU6JRWK=
Mo-T	NITlT\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqycYNUUUN3ME2xMlkxODN7IN88US=>	NH[zNlJUSU6JRWK=
HCC1395	M{DoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TibWlEPTB;MT65Nlg3OyEQvF2=	NHvYeJdUSU6JRWK=
HC-1	NELIdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjvO\|NFUUN3ME2xMlk{PDdizszN	MVzTRW5ITVJ?
HPAF-II	M4LQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInSNotKSzVyPUGuPVQ1OThizszN	MoXiV2FPT0WU
CPC-N	NUn4RWpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr6ZmdQUUN3ME2xMlk5ODB{IN88US=>	MoD1V2FPT0WU
MKN45	NVjafGZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHHTWM2OD1zLkm5NVE6KM7:TR?=	NWnHb4l4W0GQR1XS
NCI-H1693	M1vve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\VTWM2OD1{LkCwOFM{KM7:TR?=	NHrT[HJUSU6JRWK=
SHP-77	NFTw[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJwMEC1N\|Mh\|ryP	Mn;pV2FPT0WU
NCI-H1522	NUT0[XgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILTXplKSzVyPUKuNFE4OjRizszN	NF3PS4ZUSU6JRWK=
SW1573	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37STmlEPTB;Mj6wNlIh\|ryP	Mm\sV2FPT0WU
DBTRG-05MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ETWM2OD1{LkC2NFg4KM7:TR?=	M3Xmb3NCVkeHUh?=
SCC-4	M1KyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTBUXZpUUN3ME2yMlE1OzFizszN	NVPuToRJW0GQR1XS
DMS-153	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\sZpBPUUN3ME2yMlE3PjZ6IN88US=>	M3zXfnNCVkeHUh?=
MDA-MB-415	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTJwMUe1NkDPxE1?	MkizV2FPT0WU
NCI-H2126	M4DPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvFTWM2OD1{LkKyPFg5KM7:TR?=	NUPT[FVJW0GQR1XS
MDA-MB-453	NIXyUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3YdYlyUUN3ME2yMlI{OzJizszN	MkXrV2FPT0WU
U-87-MG	M4XDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF20[4pKSzVyPUKuNlg2QTJizszN	Ml\EV2FPT0WU
LNCaP-Clone-FGC	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2n0cWlEPTB;Mj6zNFExOiEQvF2=	NVHqfVRYW0GQR1XS
NCI-H1581	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjUTWM2OD1{LkOyNVA2KM7:TR?=	M4DNUnNCVkeHUh?=
BC-3	NFjncHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fZfGlEPTB;Mj6zOlUxQSEQvF2=	Mn\1V2FPT0WU
HCC38	NIO3S2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnyTWM2OD1{LkO4OFQ4KM7:TR?=	NGLvbFJUSU6JRWK=
HCC2218	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnmTYNKSzVyPUKuOFA5ODlizszN	M2nSSXNCVkeHUh?=
RO82-W-1	NHzreGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULFfIU5UUN3ME2yMlQyOjVizszN	M3TGWnNCVkeHUh?=
C2BBe1	M4HIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\HTWM2OD1{LkSxOVc5KM7:TR?=	MXfTRW5ITVJ?
LAMA-84	NEe2UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnETWM2OD1{LkW3N\|Y5KM7:TR?=	MV\TRW5ITVJ?
GMS-10	NXrUZVFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHOTWM2OD1{LkW3OlEyKM7:TR?=	Ml;RV2FPT0WU
GCT	NVHBd2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\TTWM2OD1{LkW4Olk1KM7:TR?=	MXPTRW5ITVJ?
SK-CO-1	M4mwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jTVWlEPTB;Mj62NVY3KM7:TR?=	MnzTV2FPT0WU
NCI-H526	NV\4R\|ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED0ZolKSzVyPUKuOlM1PSEQvF2=	NGXDSGVUSU6JRWK=
SW1088	NI\LXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[wd2lEPTB;Mj63O\|g{QSEQvF2=	M32xc3NCVkeHUh?=
HT55	NUfB[JQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rWPWlEPTB;Mj63PFY6PSEQvF2=	NInYOFNUSU6JRWK=
NB10	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;iWGlEPTB;Mj64NVc1QCEQvF2=	Mn[3V2FPT0WU
UACC-893	Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnKzTWM2OD1{Lki1O\|Q6KM7:TR?=	M1TuOHNCVkeHUh?=
NCI-H1618	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzqTWM2OD1{Lki4NVU{KM7:TR?=	M2LWUHNCVkeHUh?=
NCI-H1092	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTEPGZCUUN3ME2zMlA4QDF{IN88US=>	MYjTRW5ITVJ?
SBC-1	NHnDbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmSwTWM2OD1\|LkC4OVU{KM7:TR?=	MUfTRW5ITVJ?
NCI-H1623	M4HxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\lTWM2OD1\|LkC5N\|Qh\|ryP	NYP3OmkyW0GQR1XS
SiHa	M4rQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\seldKSzVyPUOuNVE6PzdizszN	M3jmSnNCVkeHUh?=
D-263MG	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1OyVWlEPTB;Mz6xOFc5QCEQvF2=	MVnTRW5ITVJ?
NCI-H1573	M3HpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUflXXRGUUN3ME2zMlE6PjRzIN88US=>	MVfTRW5ITVJ?
NCI-H82	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fr[WlEPTB;Mz6zOFQ{QSEQvF2=	NFvCfZJUSU6JRWK=
NCI-H2196	M1jxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTNwM{WwNFgh\|ryP	M4jGOXNCVkeHUh?=
MFM-223	M{H2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrKTWM2OD1\|LkO3N\|UyKM7:TR?=	Mm\KV2FPT0WU
COLO-678	NHToUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTwTWM2OD1\|LkO4NVg3KM7:TR?=	NFW2VGJUSU6JRWK=
EW-3	M1;WTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jBbGlEPTB;Mz60NFk2KM7:TR?=	MWrTRW5ITVJ?
MHH-NB-11	NILQOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrTem4xUUN3ME2zMlQ1ODZ7IN88US=>	MVnTRW5ITVJ?
EM-2	NHnObZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnlUolKSzVyPUOuOlM6QCEQvF2=	MWTTRW5ITVJ?
FTC-133	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfZbYwzUUN3ME2zMlY2PDV6IN88US=>	MnTlV2FPT0WU
NCI-H209	NIrhUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37nfWlEPTB;Mz62O\|Y2OyEQvF2=	MVTTRW5ITVJ?
TGBC24TKB	NIHIOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVH1[IxoUUN3ME2zMlY5OzV3IN88US=>	NWPBWI5[W0GQR1XS
LC-1F	M3fNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrsbGlKSzVyPUOuO\|E4PjRizszN	NWTqWIp4W0GQR1XS
C-4-II	NGDufYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvVUmN3UUN3ME2zMlc2PjR\|IN88US=>	MomwV2FPT0WU
NCI-H1650	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLZTWM2OD1\|Lke4OFU2KM7:TR?=	M3;CUHNCVkeHUh?=
JVM-2	NWfOUmk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTNwOUO2N\|kh\|ryP	M4fnN3NCVkeHUh?=
CaR-1	NUOwSFBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTNwOUe2NVch\|ryP	MmfpV2FPT0WU
MDA-MB-134-VI	M{WxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnFTWM2OD12LkCyPVUzKM7:TR?=	M1O2d3NCVkeHUh?=
NCI-H719	NWfRfJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;hW2lEPTB;ND6xOVM5QCEQvF2=	M4\WOXNCVkeHUh?=
GOTO	NWrDfWc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofLTWM2OD12LkK5O\|A2KM7:TR?=	NWOzbGJxW0GQR1XS
NCI-N87	M{DXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MontTWM2OD12LkO4PFIyKM7:TR?=	NXPHbng5W0GQR1XS
NB6	NHvaT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\LTWM2OD12LkSyOVA6KM7:TR?=	M3W5[3NCVkeHUh?=
DSH1	NXHU[IdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWK3RXZsUUN3ME20MlQ4OTF4IN88US=>	M17CRnNCVkeHUh?=
BT-20	NXrMWYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXtTWM2OD12LkS5NFAzKM7:TR?=	NF;2U5VUSU6JRWK=
NCI-H1882	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPkfHJKSzVyPUSuOVA2PyEQvF2=	NHrPRXNUSU6JRWK=
WM-115	NITPclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PLTGlEPTB;ND61NFg5OSEQvF2=	MX3TRW5ITVJ?
SKG-IIIa	NHn4OY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTRwNke3O{DPxE1?	M{PIZnNCVkeHUh?=
NCI-H69	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Pxd2lEPTB;ND63NFI4PSEQvF2=	MnTZV2FPT0WU
MSTO-211H	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml74TWM2OD12LkizOVY2KM7:TR?=	NFrmb2FUSU6JRWK=
Mewo	NHTWclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTpSWVHUUN3ME20Mlk3OzF\|IN88US=>	MkPtV2FPT0WU
GI-ME-N	NVThOphJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[4d2lEPTB;NT6wNFUxQSEQvF2=	NUO3eIdwW0GQR1XS
T98G	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfkWZhKSzVyPUWuNFY2ODhizszN	NUnZZm5KW0GQR1XS
ECC4	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTVwMEmzO\|Ih\|ryP	NFLqVVRUSU6JRWK=
EW-11	NH3wZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3DeXZQUUN3ME21MlE5ODl7IN88US=>	NX;xUZA2W0GQR1XS
COLO-800	Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPpTWM2OD13LkG5N\|Q6KM7:TR?=	MX;TRW5ITVJ?
NCI-H1755	M4DMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXafXhlUUN3ME21MlI{ODJ5IN88US=>	MljBV2FPT0WU
KMS-12-PE	M4n2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTVwM{WwPFUh\|ryP	MWjTRW5ITVJ?
HCC1954	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXtTWM2OD13Lki1PVcyKM7:TR?=	M{XGTXNCVkeHUh?=
NCI-H187	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;QN\|VFUUN3ME21MlkzQTh7IN88US=>	MWrTRW5ITVJ?
LU-165	NWjDZZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;JTWM2OD13Lkm5NFAzKM7:TR?=	MWHTRW5ITVJ?
YAPC	NUfyWmpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PmU2lEPTB;NT65PVA3QCEQvF2=	M2HQcXNCVkeHUh?=
LU-139	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rRfmlEPTB;Nj6wPFM3QCEQvF2=	M2HoNXNCVkeHUh?=
D-502MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjYfHNuUUN3ME22MlMzODR5IN88US=>	MU\TRW5ITVJ?
IST-SL1	M4\re2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHMT21KSzVyPU[uOVM6PDhizszN	M2LsWXNCVkeHUh?=
DG-75	M4HBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlL5TWM2OD14Lki4O\|g3KM7:TR?=	MV7TRW5ITVJ?
NCI-H1155	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTnem9yUUN3ME22Mlk2PThzIN88US=>	M3nLbHNCVkeHUh?=
EFE-184	NH\ZXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTdwM{G2PVUh\|ryP	NHXDe\|hUSU6JRWK=
AsPC-1	NGDEbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LXSWlEPTB;Nz60PFgxPyEQvF2=	M3WwOnNCVkeHUh?=
SW948	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPE[lRxUUN3ME23MlU5Ozl3IN88US=>	M2LmbHNCVkeHUh?=
NCI-H524	M3vsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[4OWlEPTB;OT61PFYzQCEQvF2=	NEnCXFZUSU6JRWK=
KOSC-2	NG\Q[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjjXZNiUUN3ME25MlYzQDN2IN88US=>	NW\j[pFpW0GQR1XS
T-24	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzROFhKUUN3ME25Mlk1PDF3IN88US=>	MnvsV2FPT0WU
NCI-H748	M3uxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:zeGV1UUN3ME2xNE43Ozl5IN88US=>	M4fFT3NCVkeHUh?=
NCI-H23	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETkSVRKSzVyPUGwMlY1PDJizszN	NV3zboZSW0GQR1XS
UACC-812	M{\tZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1njOWlEPTB;MUGuO\|E4KM7:TR?=	MXHTRW5ITVJ?
SCLC-21H	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrtTWM2OD1zMj6xOVUyKM7:TR?=	M2DXeHNCVkeHUh?=
NCI-SNU-16	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;GcmlEPTB;MUOuNVI2QCEQvF2=	NYLQeo9nW0GQR1XS
HD-MY-Z	M3PMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WyO2lEPTB;MUSuOlM3OyEQvF2=	MnH6V2FPT0WU
SK-N-FI	NYDRc3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF2Lki5NVIh\|ryP	M{TzenNCVkeHUh?=
LB647-SCLC	NYTydZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTF3LkexPVUh\|ryP	NXn1NoNiW0GQR1XS
NCI-H345	M1vpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTJOVduUUN3ME2xO{4{PDNizszN	MXHTRW5ITVJ?
NCI-H1563	NVPGSXVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlmwTWM2OD1zOD63OlAyKM7:TR?=	NV7rVlRsW0GQR1XS
RL	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;3XWlHUUN3ME2yNU4zPjV4IN88US=>	MWnTRW5ITVJ?
KY821	NUD4OIJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTJ{LkC1OVMh\|ryP	NX7JZ4JFW0GQR1XS
JVM-3	M{HPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTJ3LkC0NVMh\|ryP	NILhdWZUSU6JRWK=
NCI-H1793	NFSw[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJ6LkW0PVkh\|ryP	MoezV2FPT0WU
LU-134-A	M2DHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfEeXZKSzVyPUOwMlIxOzdizszN	MlnvV2FPT0WU
NCI-H1395	M2n4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHVTWM2OD1\|Mj6yOFMyKM7:TR?=	NGKyO3JUSU6JRWK=
NCI-H1993	M2C2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rsNmlEPTB;M{KuPFIyQCEQvF2=	M4fRT3NCVkeHUh?=
P31-FUJ	NWftblhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzRO3FKSzVyPUOzMlQ5QTlizszN	NV3lUnRqW0GQR1XS
LS-513	NIHoS\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jhWGlEPTB;M{WuPFg4QSEQvF2=	NVW0fHk5W0GQR1XS
SK-MEL-1	NHO2dIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTEZnVKSzVyPUSwMlM1QTlizszN	NWCwOZhwW0GQR1XS
SW684	NWnLTIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe5S5duUUN3ME20N{46PjZzIN88US=>	NUPVfW1qW0GQR1XS
COR-L88	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXu5R4JZUUN3ME20OE4xPjZ3IN88US=>	NYP6NmhPW0GQR1XS
NCI-H889	M4PWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTR3LkCwPFch\|ryP	NVXkcGNTW0GQR1XS
TALL-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjWV4FIUUN3ME20Ok4yOTl7IN88US=>	Mo\oV2FPT0WU
KARPAS-299	NYGyNHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTR5LkG5PVMh\|ryP	MVvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00438178	Completed	Drug: Obatoclax mesylate (GX15-070MS)	Hematological Malignancies	Gemin X\|Teva Pharmaceutical Industries	October 2005	Phase 1
NCT00600964	Completed	Drug: GX15-070MS	Chronic Lymphocytic Leukemia	Gemin X\|Teva Pharmaceutical Industries	September 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 51 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 51 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)